STOCKS TELEGRAPH

Tag: PRME Stock

  • Prime Medicine (PRME) Stock Jumps Following Strategic Collaboration News

    Prime Medicine (PRME) Stock Jumps Following Strategic Collaboration News

    The stock value of Prime Medicine, Inc. (NASDAQ: PRME) is increasing significantly on the US stock charts today, indicating that the market is enthusiastic about the company’s recent announcement of expansion plans. As of the most recent market check, PRME shares were surging 12.72% to trade at $3.90.

    Prime Medicine Inked a Strategic Partnership

    In order to develop reagents for state-of-the-art ex vivo T-cell therapy, Prime Medicine (PRME) has entered into a strategic research partnership and license agreement with Bristol Myers Squibb.

    As per the cooperation agreement, PRME will create Prime Editor reagents specifically designed for certain uses, such utilizing its innovative Prime Assisted Site-certain Integrase Gene Editing (PASSIGE) technology.

    These next-generation cell treatments will be developed, manufactured, and commercialized by Bristol Myers Squibb, with Prime Medicine providing critical support in the development of reagents and gene editing technologies.

    Advancing Gene Editing Technology

    This collaboration represents a significant opportunity for the company to extend its Prime Editing technology beyond its current focus on rare genetic disorders. The partnership is poised to address critical unmet needs in the fields of immunology and oncology, leveraging Prime Medicine’s PASSIGE technology.

    This advanced approach integrates Prime Editing with an integrase or site-specific recombinase, allowing for the introduction of large gene-sized cargo into the genome. Remarkably, PASSIGE employs a completely non-viral manufacturing process, avoiding double-stranded DNA breaks and off-target edits, thereby enabling more precise genetic modifications.

    Financial Implications and Future Prospects

    The agreement not only enhances Prime Medicine’s research capabilities but also promises substantial financial rewards. As per the agreement, Bristol Myers Squibb will invest $55 million in equity and Prime Medicine would get an upfront payment of $55 million.

    In addition, the business is qualified for royalties on net sales and approximately $3.5 billion in milestone payments, comprising over $2.1 billion in commercialization milestones and $1.4 billion in development milestones.

  • Onward and Upward: Prime Medicine’s (PRME) Extended-Session Rally

    Onward and Upward: Prime Medicine’s (PRME) Extended-Session Rally

    In the extended session on Monday, the rally for Prime Medicine, Inc. (NASDAQ: PRME) stock persisted, with a noteworthy 5.61% surge after-hours, reaching $6.78. This surge further augmented the rise during regular trading hours, culminating at $6.42, marking a substantial 14.44% increase. The escalation in PRME stock value coincides with an imminent significant event.

    Executive Participation At BioConnect Investor Conference

    Prime Medicine (PRME) disclosed that its Chief Financial Officer, Allan Reine, M.D., is slated to engage in a fireside chat during the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, scheduled for Monday, May 20, 2024. Dr. Reine will delve into discussions encompassing the preclinical data showcasing the efficacy of its ex vivo Prime Editing program, PM359.

    Innovative Prime Editing In Focus

    Recent revelations from Prime Medicine shed light on new data concerning PM359, aimed at rectifying a prevalent disease-causing mutation associated with chronic granulomatous disease (CGD). These findings were presented at an oral session during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore.

    Noteworthy is the clearance of PRME’s investigational new drug (IND) application for PM359 by the U.S. Food and Drug Administration (FDA) for CGD treatment. This development marks a significant milestone, showcasing the transformative potential of Prime Editing technology.

    Addressing A Rare Genetic Disorder

    CGD, a rare hereditary ailment, poses significant health challenges, often leading to recurrent and severe infections. The disorder arises from mutations affecting the NADPH oxidase complex, impairing the body’s ability to combat infections effectively. Prime Medicine’s pioneering ex vivo Prime Editing program, PM359, targets the correction of the predominant mutation in CGD patients’ CD34+ hematopoietic stem cells (HSCs), with promising results observed in preclinical studies.

    The restoration of neutrophil function post-stem cell engraftment in animal models underscores the therapeutic potential of this innovative approach, signaling hope for patients grappling with this debilitating condition. Notably, results showed that neutrophil function could be restored in mice following stem cell engraftment and that Prime Edited cell output could be increased to a therapeutic size.